Johnson & Johnson (JNJ) is facing multiple lawsuits related to its talc products with cancer victims accusing them of fraudulent bankruptcies. The company proposes a $6.5 billion settlement. Despite these, JNJ has strong financials and maintains a positive outlook. Recent reports show compelling valuation and positive expert ratings overshadowing some controversies. In terms of innovation, JNJ was named in Fortune's 2024 Most Innovative Companies list while promising phase 3 results for Tremfya in treating Crohn’s disease were revealed. JNJ's drug portfolio has bolstered with the acquisition of Proteologix and the plans to extend the VERMOX® donation program. A $3.75 billion deal is underway to offload remaining Kenvue stake. JNJ's commitment to diversity, equity, and inclusion are apparent while the company was also named the most admired company in 2024. It continues to earn from its dividend while cautiously selling US$6.8m of stock. Finally, JNJ acquisitions include the consideration of a deal for Shockwave Medical and the purchase of Proteologix adding to the medical device portfolio.
Johnson Johnson JNJ News Analytics from Thu, 20 Jul 2023 07:00:00 GMT to Thu, 23 May 2024 20:33:41 GMT -
Rating 5
- Innovation 7
- Information 10
- Rumor +6
